Clinical Trials
5 trialsNCT01409161 2026-05-20
Tretinoin and Arsenic Trioxide With or Without Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT04793919 2024-04-15
Treatment Study for Children and Adolescents With Acute Promyelocytic Leukemia
Associazione Italiana Ematologia Oncologia Pediatrica
Phase 2 Recruiting
NCT00413166 2019-05-07
All-trans Retinoic Acid, and Arsenic +/- Idarubicin
M.D. Anderson Cancer Center
Phase 2 Completed
NCT01548911 2018-07-02
Gemtuzumab Ozogamicin in Treating Patients With Acute Myeloid Leukemia
Wake Forest University Health Sciences
Phase 2 Withdrawn
NCT01869803 2018-03-02
Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Acute Promyelocytic Leukemia
Wake Forest University Health Sciences
Approved for marketing